Entera Bio (NASDAQ:ENTX) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Entera Bio (NASDAQ:ENTX) in a report issued on Monday,Benzinga reports. HC Wainwright currently has a $10.00 price target on the stock.

A number of other equities research analysts have also recently commented on ENTX. Wall Street Zen raised Entera Bio to a “sell” rating in a research note on Saturday, December 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Entera Bio in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $10.00.

Entera Bio Stock Performance

Shares of ENTX opened at $1.33 on Monday. Entera Bio has a fifty-two week low of $1.00 and a fifty-two week high of $3.22. The firm’s 50-day simple moving average is $1.72 and its two-hundred day simple moving average is $2.03. The stock has a market cap of $60.99 million, a PE ratio of -5.32 and a beta of 1.84.

Entera Bio (NASDAQ:ENTX) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02. Equities research analysts predict that Entera Bio will post -0.28 EPS for the current year.

Institutional Trading of Entera Bio

Several large investors have recently modified their holdings of ENTX. Bessemer Group Inc. bought a new position in Entera Bio in the second quarter valued at about $268,000. HighTower Advisors LLC increased its position in shares of Entera Bio by 137.8% during the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock valued at $84,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Citadel Advisors LLC lifted its stake in shares of Entera Bio by 243.0% in the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock worth $77,000 after purchasing an additional 28,322 shares during the period. Institutional investors own 14.11% of the company’s stock.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.